Products
Abrezekimab Biosimilar Fab Antibody Fragment (IL-13) for Research
Pre-Made Abrezekimab biosimilar, Fab, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abrezekimab (formerly VR 942) a biologic immunomodulatory product, is being developed by UCB and Vectura Group for the treatment of severe inflammatory.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-004-1mg | 1mg | 3090 |
| GMP-Bios-ab-004-10mg | 10mg | |
| GMP-Bios-ab-004-100mg | 100mg | |
| GMP-Bios-ab-004-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Abrezekimab biosimilar, Fab, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody |
| INN Name | Abrezekimab |
| Target | IL13 |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | UCB |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Asthma |
| Development Tech | na |
About target - IL13
1. Protein Interleukin-13 receptor subunit alpha-1
2. Gene IL13RA1
3. Organism Homo sapiens (Human)
Function
Binds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity.
